Jupiter Topco LLC Purchases New Stake in Janux Therapeutics, Inc. $JANX

Key Points

• Jupiter Topco LLC acquired 172,229 Janux Therapeutics shares worth approximately $2.65 million, representing about 0.28% of the company. Institutional investors and hedge funds collectively own 75.39% of JANX.
• Analyst sentiment remains generally positive, with a consensus rating of “Moderate Buy” and an average price target of $36.46, although several firms recently lowered their targets.
• Janux reported a quarterly loss of $0.35 per share, missing the $0.25 expected loss, while revenue of $10.27 million came in below the $19.07 million analyst estimate.

Jupiter Topco LLC acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 172,229 shares of the company's stock, valued at approximately $2,646,000. Jupiter Topco LLC owned about 0.28% of Janux Therapeutics at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in JANX. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Janux Therapeutics in the 4th quarter worth about $34,000. Versant Capital Management Inc raised its stake in shares of Janux Therapeutics by 42.8% in the 2nd quarter. Versant Capital Management Inc now owns 2,615 shares of the company's stock valued at $40,000 after purchasing an additional 784 shares in the last quarter. Osaic Holdings Inc. lifted its position in shares of Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company's stock worth $80,000 after purchasing an additional 3,037 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Janux Therapeutics during the fourth quarter worth about $51,000. Finally, Tower Research Capital LLC TRC grew its stake in Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company's stock worth $91,000 after purchasing an additional 2,502 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently weighed in on JANX. Wedbush lowered their price objective on Janux Therapeutics from $45.00 to $36.00 and set an "outperform" rating for the company in a report on Friday, May 8th. Truist Financial reaffirmed a "buy" rating and set a $26.00 target price (down from $80.00) on shares of Janux Therapeutics in a report on Thursday, June 25th. Wolfe Research upgraded Janux Therapeutics from a "peer perform" rating to an "outperform" rating and set a $23.00 target price for the company in a research report on Monday, August 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Janux Therapeutics in a report on Monday, July 20th. Finally, Guggenheim dropped their price target on Janux Therapeutics from $58.00 to $55.00 and set a "buy" rating on the stock in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Janux Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $36.46.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $19.70 on Thursday. Janux Therapeutics, Inc. has a 1 year low of $12.12 and a 1 year high of $35.34. The firm's 50-day moving average is $16.38 and its 200-day moving average is $14.95. The company has a market cap of $1.20 billion, a P/E ratio of -12.01 and a beta of 2.53.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.10). The company had revenue of $10.27 million for the quarter, compared to analyst estimates of $19.07 million. As a group, sell-side analysts predict that Janux Therapeutics, Inc. will post -1.76 earnings per share for the current year.

Janux Therapeutics Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.

Want to see what other hedge funds are holding JANX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source